Key result
Anticoagulant use in CKD patients is linked to ~19-fold higher bleeding risk.
Why the study?
Patients with CKD frequently require anticoagulation for atrial fibrillation and venous thromboembolism, motivating evaluation of the prevalence and risk factors of bleeding across different CKD stages in patients receiving anticoagulants.
Does anticoagulation therapy increase the risk of bleeding events in patients with chronic kidney disease?
Cohort (n=305)
Yes
Does anticoagulation therapy increase the risk of bleeding events in patients with chronic kidney disease?
Bleeding complications occur in 27.9% of CKD patients cohort-wide and are strongly associated with anticoagulant use (OR 18.992), advanced G5 CKD (OR 2.412), and female sex (OR 2.024), underscoring the need for close monitoring and individualized dosing.
Answers are grounded in this paper and cite their sources.
Anticoagulant use in CKD warrants close bleeding surveillance; leaves open optimal risk stratification pending randomized confirmation.
Background Chronic kidney disease (CKD) poses a major global public health burden and is intricately associated with cardiovascular complications. In patients undergoing dialysis, the incidence of atrial fibrillation, acute coronary syndrome, and venous thromboembolism is notably elevated. Anticoagulants play a pivotal role in reducing thromboembolic events in CKD patients with atrial fibrillation and venous thromboembolism. This study aimed to determine the prevalence of bleeding and identify associated risk factors across different CKD stages in patients receiving anticoagulation therapy. Patients and methods A prospective observational cohort study was conducted at university hospitals from September, 2024 to February, 2025. It included 305 CKD patients, of whom 249 were on anticoagulants. Data collection encompassed clinical history, laboratory parameters, and follow-up for bleeding events. Results The cohort comprised 178 males and 127 females (mean age of 54.10 ± 15.77 years). Most patients (75.4%) were hemodialysis-dependent. Anticoagulant use was prevalent (81.6%), and 27.9% had a bleeding tendency. Significant associations found between bleeding and female sex [odds ratio (OR): 2.024], advanced CKD (G5 stage, OR: 2.412), and anticoagulant use (OR: 18.992). The bleeding risk was higher in patients receiving therapeutic anticoagulation (OR: 2.800) and those with longer CKD duration. Conclusion Bleeding complications are frequent in CKD patients on anticoagulants, especially in advanced stages. Individualized anticoagulation strategies and close monitoring are essential to balance thrombotic and hemorrhagic risks.
No takes yet. Share an insight, caveat, or question.
Youssif et al. (2026) conducted a cohort in Chronic kidney disease (n=305). Anticoagulation therapy vs. No anticoagulation therapy (56 patients not on anticoagulants) was evaluated on Prevalence of bleeding events / bleeding tendency (OR 18.992). Anticoagulant use in CKD patients was strongly associated with bleeding, along with advanced G5 stage CKD and female sex.
Synapse has enriched 10 related papers. Consider them for comparative context: